Definitive Contract HHSO100200600017C

This definitive contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent BioSolutions Canada Inc., a for-profit organization, is valued at $26,553,434.00. The contract is for the supply of VIGIV, a medical countermeasure against chemical, biological, radiological, and nuclear threats. As a prime contractor, Emergent BioSolutions has received over $770 million in federal contracts from agencies like the Defense Logistics...

This is a $65,806,649.98 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Biofactura Inc. for preclinical and manufacturing development activities. The contract includes cell line development, process development, non-clinical efficacy and safety studies, manufacturing, and clinical activities. The contract was awarded on September 26, 2019 with an ultimate completion date of March 30, 2029. The contract has no...

<p>This is a firm fixed-price delivery order contract awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Sanofi Pasteur Biologics, LLC, for partial kits. The contract has a ceiling value of $1,594,330.00 and an ultimate completion date of June 23, 2016. The contract is not designated as a set-aside. No additional context or subcontractor information is provided.</p>

This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines &amp; Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...

This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Macrogenics, Inc., a for-profit manufacturer, for research and development services related to advanced development. The contract has a ceiling value of $56,058,625.93 and was awarded on September 29, 2006, with an ultimate completion date of September 28, 2011. The contract is not set-aside for any...

This is a $8,650,565,549.53 Firm Fixed Price definitive contract awarded to Pfizer Inc. by the Office of the Assistant Secretary for Preparedness and Response (ASPR) for the provision of COVID-19 vaccines. The contract has an ultimate completion date of May 29, 2024 and was awarded on October 1, 2022 without any set-aside designation. Pfizer, a global pharmaceutical manufacturer, is the prime contractor for this award. The contract supports the government's COVID-19 vaccine initiatives and is...

<p>This is a cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Janssen Vaccines &amp; Prevention B.V. (JPC), a foreign-owned for-profit organization. The $196,408,488.00 contract does not have a set-aside designation and has an ultimate completion date of March 30, 2026. The contract was awarded on September 28, 2017.</p>

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...

This is a federal contract award with ID HHSO100200600011C, made by the Office of the Assistant Secretary for Preparedness and Response (a civilian agency) to the vendor Glaxosmithkline Holdings (Americas) Inc. The contract is for DRUGS AND BIOLOGICALS under the PANDEMIC INFLUENZA PREPAREDNESS major program, with a Definitive Contract type and Cost No Fee pricing. The contract has a ceiling value of $72,766,563.54 and an ultimate completion date of April 30, 2015. There was no set-aside used for...

This is a $256,404,564 definitive contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biosolutions Canada Inc. for the supply of Botulism Antitoxin Heptavalent (BAT) to treat botulism. The contract has a period of performance through March 31, 2029. This is a follow-on contract to a previous award and Emergent was selected as the sole source provider given its capability to manufacture the...